Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 5 The receptor-active 61-residue recombinant neuregulin-1 peptide (rhNRG-1) improves doxorubicin-induced and Coxsackie B3 (CV-B3)-induced myocardial pathology. Transverse sections of myocardium obtained after: no treatment (control) (a), doxorubicin (3.3 mg/kg, IV, once weekly for 4 weeks) plus vehicle (b), or doxorubicin + rhNRG-1 (20 µg/kg/day for the first 7 days) (c) treatment of rats; or no treatment (control) (d ), CV-B3 infection of mice + vehicle (e), or CV-B3 + NRG-1 (30 µg/kg/day, IV, for 5 days) (f). Staining: hematoxylin and eosin; magnification: x 10; white space bar (a) = 50 µm. Arrows indicate areas of necrosis (b) and lymphocytic infiltration (e), which are much less apparent with rhNRG-1 treatment (c, f).
|
